company background image
LXRX

Lexicon Pharmaceuticals NasdaqGS:LXRX Stock Report

Last Price

US$2.03

Market Cap

US$303.7m

7D

39.0%

1Y

-64.5%

Updated

26 Jun, 2022

Data

Company Financials +
LXRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

LXRX Stock Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.

Lexicon Pharmaceuticals Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Lexicon Pharmaceuticals
Historical stock prices
Current Share PriceUS$2.03
52 Week HighUS$6.33
52 Week LowUS$1.31
Beta1.53
1 Month Change20.83%
3 Month Change-2.87%
1 Year Change-64.51%
3 Year Change-67.73%
5 Year Change-87.66%
Change since IPO-98.45%

Recent News & Updates

Jun 15
Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

May 31

Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here. It may not be a bad idea to take the plunge.

Shareholder Returns

LXRXUS BiotechsUS Market
7D39.0%10.3%6.6%
1Y-64.5%-24.3%-18.4%

Return vs Industry: LXRX underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: LXRX underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is LXRX's price volatile compared to industry and market?
LXRX volatility
LXRX Average Weekly Movement12.4%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: LXRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: LXRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199587Lonnel Coatshttps://www.lexpharma.com

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals Fundamentals Summary

How do Lexicon Pharmaceuticals's earnings and revenue compare to its market cap?
LXRX fundamental statistics
Market CapUS$303.67m
Earnings (TTM)-US$90.28m
Revenue (TTM)US$308.00k

990.2x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LXRX income statement (TTM)
RevenueUS$308.00k
Cost of RevenueUS$57.36m
Gross Profit-US$57.05m
Other ExpensesUS$33.22m
Earnings-US$90.28m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.60
Gross Margin-18,524.35%
Net Profit Margin-29,310.39%
Debt/Equity Ratio25.3%

How did LXRX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LXRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LXRX?

Other financial metrics that can be useful for relative valuation.

LXRX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue787.9x
Enterprise Value/EBITDA-2.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does LXRX's PB Ratio compare to its peers?

LXRX PB Ratio vs Peers
The above table shows the PB ratio for LXRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.5x

Price-To-Book vs Peers: LXRX is expensive based on its Price-To-Book Ratio (3.3x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does LXRX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: LXRX is expensive based on its Price-To-Book Ratio (3.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is LXRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LXRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LXRX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LXRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LXRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LXRX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LXRX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Lexicon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LXRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LXRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LXRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LXRX's revenue (117.5% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: LXRX's revenue (117.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LXRX is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Lexicon Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


25.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LXRX is currently unprofitable.

Growing Profit Margin: LXRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LXRX is unprofitable, but has reduced losses over the past 5 years at a rate of 25% per year.

Accelerating Growth: Unable to compare LXRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LXRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: LXRX has a negative Return on Equity (-97.39%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Lexicon Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: LXRX's short term assets ($88.4M) exceed its short term liabilities ($18.9M).

Long Term Liabilities: LXRX's short term assets ($88.4M) exceed its long term liabilities ($24.6M).


Debt to Equity History and Analysis

Debt Level: LXRX has more cash than its total debt.

Reducing Debt: LXRX's debt to equity ratio has reduced from 75.2% to 25.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LXRX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LXRX has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.4% each year.


Discover healthy companies

Dividend

What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LXRX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LXRX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.9yrs

Average management tenure


CEO

Lonnel Coats (56 yo)

7.92yrs

Tenure

US$3,924,090

Compensation

Mr. Lonnel Coats has been the Chief Executive Officer of Lexicon Pharmaceuticals, Inc., since July 7, 2014. He was President of Lexicon Pharmaceuticals, Inc since July 7, 2014 until October 01, 2021. Mr. C...


CEO Compensation Analysis

Compensation vs Market: Lonnel's total compensation ($USD3.92M) is above average for companies of similar size in the US market ($USD2.84M).

Compensation vs Earnings: Lonnel's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: LXRX's management team is seasoned and experienced (7.9 years average tenure).


Board Members

Experienced Board: LXRX's board of directors are seasoned and experienced ( 14.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

Lexicon Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Lexicon Pharmaceuticals, Inc.
  • Ticker: LXRX
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$303.675m
  • Shares outstanding: 149.59m
  • Website: https://www.lexpharma.com

Number of Employees


Location

  • Lexicon Pharmaceuticals, Inc.
  • 2445 Technology Forest Boulevard
  • 11th Floor
  • The Woodlands
  • Texas
  • 77381
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.